Quanterix Corporation and Akoya Biosciences, Inc. announced an amendment to the terms of their previously announced merger agreement on April 28, 2025. Under the revised terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders.
Each Akoya share will now receive $0.38 in cash and 0.1461 shares of Quanterix common stock. This amended exchange ratio means Quanterix will issue over 9 million fewer shares than under the original deal terms, with Quanterix shareholders owning approximately 84% and Akoya shareholders approximately 16% of the combined company.
A significant change is that Quanterix will no longer hold its previously announced special meeting of shareholders, as the revised terms were approved by the Quanterix Board and the Akoya Board. Akoya shareholders holding more than 50% of Akoya’s common stock have agreed to vote in favor of the merger on these amended terms, with the transaction still expected to close during the second quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.